Company Overview - CareDx is a healthcare diagnostics company that specializes in advanced molecular and digital solutions for transplant patient care, focusing on organ and stem cell transplant monitoring [1] - The company generates revenue through direct sales and third-party distribution of proprietary diagnostic tests, software platforms, and related services [2] Recent Transactions - John Hanna, President and CEO of CareDx, sold 19,480 shares in multiple open-market transactions on January 21 and 22, 2026, with an aggregate transaction value of approximately $412,200 [7] - This sale was part of a Rule 10b5-1 trading plan, which allows insiders to buy and sell shares at predetermined times to avoid the appearance of insider trading [8] Insider Ownership - The transaction reduced direct holdings by 3.16%, leaving John Hanna with 597,405 directly held shares, which still represents a substantial ownership position post-sale [5] - The sale of 19,480 shares was the largest among two recent sell-only trades by John Hanna, surpassing the prior transaction of 10,156 shares [6] Financial Performance - CareDx's stock is down 9.36% over the last year and 75.4% since January 22, 2021, but its financial results and future outlook appear promising [9] - The company announced preliminary fourth-quarter revenue of approximately $108 million, an increase of 25% year over year, and full-year revenue of approximately $380 million, an increase of 14% year over year [9] - CareDx repurchased 5.8 million shares for $88 million at an average price of $15.16 per share, indicating strong cash-flow management [9] Strategic Initiatives - CareDx announced a strategic collaboration with 10x Genomics to establish a research initiative called ImmuneScape, which will study the biology of transplant organ rejection and support clinical diagnostic development [10]